Laverock Therapeutics has announced new in vivo programmes spanning CAR‑T and genetic medicine, expanding its therapeutic ...

Mums whose babies developed life‑threatening sepsis and meningitis from group B streptococcus are urging pregnant women to ...

Atrogi has announced positive human data for ATR‑258, its first‑in‑class oral GRK2‑biased β2‑adrenergic modulator designed to improve muscle function and body composition. In an 8‑week ...

Boehringer Ingelheim has reported new phase 3 data showing its dual glucagon/GLP‑1 agonist survodutide achieved weight loss of up to 13.1% in adults with obesity and type 2 diabetes. The SYNCHRONIZE‑2 ...

NICE has issued final draft guidance recommending Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome, but only when response to diet ...

Kither Biotech has started dosing patients in its phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe ...

Lexeo Therapeutics has signed an agreement to acquire Mantle Therapeutics and launched several new collaborations aimed at ...

AbbVie has received European Commission approval for Rinvoq to treat active polyarticular juvenile idiopathic arthritis in ...

It is a testament to investor success that over 100 exhibitors at CPHI 2026 have some form of PE ownership across the entire ...

Neuraxpharm and Minoryx have announced that the European Commission has granted marketing authorisation under exceptional ...

AC Immune has reported positive week-100 results from part 1 of its phase 2 VacSyn trial evaluating ACI-7104 in early-stage ...

Quotient Sciences and Acesion Pharma have formed a new collaboration to apply AI‑enhanced formulation development within Quotient’s Translational Pharmaceutics platform. The partnership will support ...